Xinruizaisheng Just Completed $1.4 Million of Series A Financing, Focusing on New Drug Development

According to VCBeat (biobeat1), on May 29, 2019, Xinruizaisheng just completed $ 1.4 million of Series A financing that was led by CASSTAR. This round of financing will be used for HR improvement and small molecule research and development.

Xinruizaisheng was founded in March 2019 at Nanking. Dr. Yang Zhao, the founder and chief scientist of Xinruizaisheng is a researcher at the Peking University Institute of Molecular Medicine, Peking-Tsinghua University Center For Life Science and National Key Laboratory of Natural Medicines and Biomimetic Drugs. Their team is mainly dedicated to the research and development of new technologies for somatic cell reprogramming and regenerative medicine to provide new solutions for the treatment of many difficult diseases such as chronic heart failure and liver failure.

Around the world, tissue fibrosis is the leading cause of many diseases that lead to disability and death. Breakthroughs in stem cell and cell reprogramming provided new directions for the development of new drugs for the treatment of these diseases. Dr. Yang Zhao and his team have made few breakthroughs in these fields and have won an award for their progress in China.

CAS Star is engaged in high-tech industry incubation and venture capital investment. It is committed to building a scientific and technological entrepreneurial ecological network system with "research institution + angel fund + incubator + entrepreneurship training" to provide professional, in-depth and comprehensive entrepreneurship for technology entrepreneurs.